Scott+Scott Attorneys at Law LLP Reminds Investors of the Ongoing Action Against Iovance Biotherapeutics, Inc. (IOVA)

New York, New York--(Newsfile Corp. - May 23, 2025) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, "Defendants"). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b5) on behalf of all persons other than Defendants who purchased or otherwise acquired Iovance securities between May 9, 2024, and May 8, 2025, inclusive (the "Class Period"), and were damaged thereby (the "Class"). The Class Action is captioned: Farberov v. Iovance Therapeutics, Inc., et al., No. 3:25-cv-04199 (N.D. Cal.).

CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION

Iovance is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies for the treatment of metastatic melanoma and other solid tumor cancers. The Company's top priority is the commercialization of Amtagvi, a tumor-derived autologous T-cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma. The Company received FDA approval for Amtagvi on February 16, 2024. The Company commercially launched Amtagvi on February 20, 2024.

The Class Action alleges that, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) new Authorized Treatment Centers ("ATCs") were experiencing longer timelines to begin treating patients with Amtagvi; (2) the Company's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; (3) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Diskutieren Sie über die enthaltenen Werte

IOVANCE Biotherapeutics Inc - Entwickler von Immuntherapieprodukten

Iovance Biotherapeutics -0,83 % Aktie

0 Aufrufe heute

Tn84 10.05.25, 16:37